Trump Administration’s 2025‑2026 Health Policy Overhaul: HHS Cuts, Executive Orders & Vaccine Shifts

In the first months of President Donald J. Trump’s second term, a cascade of executive orders, agency rules and budget proposals reshaped the United States public‑health landscape, affecting everything from data transparency to vaccine policy and federal research funding.

Executive actions that altered federal health data and programs

On Jan. 20, 2025, President Trump issued executive orders that revoked many Biden‑era directives and introduced new guidance on “gender ideology,” DEI, and merit‑based opportunities. In response, HHS removed thousands of health‑related websites and databases covering DEI, LGBTQ, reproductive health, HIV/AIDS research and health disparities. A lawsuit was filed to reverse the deletions, and by Sep. 2025 the administration agreed to restore the sites to their Jan. 29 versions.

Later, on Feb. 14, 2025, another executive order prohibited federal funding for schools or universities that required COVID‑19 vaccination, prompting all 15 colleges with such mandates to drop them by mid‑March.

Leadership changes and policy priorities

Robert F. Kennedy, Jr. Was confirmed as HHS Secretary on Feb. 13, 2025 (52‑48 vote). In his first staff address on Feb. 18, he pledged to investigate the childhood vaccine schedule, combat what he called a “chronic disease epidemic,” and increase transparency.

On Feb. 13, the president also created the “Make America Healthy Again” (MAHA) commission, tasking it with a 100‑day assessment and a 180‑day strategy to curb childhood chronic disease.

Regulatory and funding shifts

NIH announced a new 15 % standard indirect‑cost rate on Feb. 7, 2025, a reduction that would have cut research institution overhead. The policy was blocked by a series of court orders, and the prior rates remain in effect while litigation continues.

In March, HHS withdrew the Surgeon General’s 2024 warning that gun violence is a public‑health crisis and eliminated related staff positions.

On Mar. 25, HHS and CDC announced plans to pull $11.4 billion of supplemental COVID‑19 and pandemic response funding from state and local health departments. A coalition of 23 states sued; courts have blocked the pullback and most of the funds have been restored for those states.

HHS also issued a Feb. 28 rule ending the public‑comment requirement for many grant and contract decisions, streamlining policy changes but reducing external input.

Vaccine policy overhauls

From Feb. 14 onward, the administration took multiple steps to reshape vaccine guidance: removing ACIP members on Jun. 9, 2025; restricting ACIP working‑group participation for external medical societies on Aug. 1; and, on May 27, 2025, announcing that CDC would no longer recommend COVID‑19 vaccination for healthy pregnant women and children—a departure from standard ACIP processes.

In April, the FDA required expanded myocarditis warnings on mRNA COVID‑19 vaccines, and in July ACIP voted to ban thimerosal in multi‑dose flu vaccines and to recommend RSV products for infants and older adults.

By Jan. 5, 2026, HHS released a revised childhood immunization schedule that reduced routine recommendations from 17 to 11 diseases, moving five vaccines (including rotavirus, influenza, hepatitis A, hepatitis B and meningococcal) to “shared clinical decision‑making.”

Research funding and program cuts

NIH terminated several HIV prevention and vaccine grants in March 2025, and in May 2025 ended funding for two HIV vaccine projects focused on broadly neutralizing antibodies.

In May, the White House issued an executive order tightening oversight of “gain‑of‑function” research, which could limit certain high‑risk studies while aiming to improve bio‑security.

Barra’s 2025‑2026 budget request called for steep cuts to HHS agencies (CDC, HRSA, SAMHSA, NIH) and eliminated the Hospital Preparedness Program, though Congress has not yet adopted those cuts.

Public‑health initiatives and controversies

HHS launched a $500 million “next‑generation universal vaccine platform” on May 1, 2025, repurposing funds from the Biden administration’s NextGen COVID‑19 effort.

In September 2025, the administration announced autism‑related actions, including FDA authorization of leucovorin for certain children with autism and a proposed safety label change for acetaminophen, despite longstanding scientific consensus that vaccines do not cause autism.

Later that month, CDC’s website was altered to state that studies have not ruled out a possible link between infant vaccines and autism, prompting criticism from major medical societies.

Potential future developments

Legal challenges to the HHS website removals, ACIP restructuring and funding cuts could result in further court‑ordered reinstatements if judges deem actions unlawful. Ongoing litigation over the NIH indirect‑cost rate may eventually set a precedent for how federal grant overhead is calculated.

Analysts expect that if the administration proceeds with the “shared clinical decision‑making” model for several vaccines, insurance coverage could become more variable, depending on provider recommendations and state Medicaid policies.

Future budget cycles may either cement the proposed agency reductions or, if Congress rejects the cuts, restore funding to key public‑health programs such as CDC’s injury‑prevention unit and the Hospital Preparedness Program.

Frequently Asked Questions

Why were thousands of HHS health‑related websites removed in early 2025?

Following executive orders that targeted DEI, LGBTQ and related topics, HHS removed the sites and databases deemed to contain such content. A lawsuit sought to reverse the deletions, and the administration later agreed to restore the sites to their Jan. 29, 2025 versions.

What changes did the administration make to the federal childhood vaccination schedule?

In Jan. 5, 2026, HHS issued a memo reducing routine vaccine recommendations from 17 to 11 diseases. Five vaccines (rotavirus, influenza, hepatitis A, hepatitis B, meningococcal) were shifted to “shared clinical decision‑making,” and the HPV schedule was trimmed to a single dose.

How has the COVID‑19 vaccine recommendation process been altered?

In May 2025, Secretary Kennedy announced that CDC would no longer recommend COVID‑19 vaccines for healthy pregnant women and children, moving from a universal recommendation to a “shared decision‑making” approach. The FDA now requires randomized, placebo‑controlled trials for new COVID‑19 booster approvals for individuals not at higher risk.

How might these policy shifts affect your community’s access to public‑health resources?